子痫前期筛查:为美国预防服务工作组提供的证据报告与系统综述
该系统综述纳入21项研究(13982名参与者),未发现直接比较筛查与不筛查效果的研究;外部验证的风险预测模型适用性有限且缺乏校准数据;疑似子痫前期孕妇尿蛋白检测准确性差异大;证据不足以支持常规筛查。
要点
- 无研究直接比较子痫前期筛查人群与未筛查人群的效果。
- 16个风险预测模型中5个c统计量>0.80,但最大验证队列阳性预测值仅4%。
- 疑似子痫前期孕妇尿蛋白检测灵敏度22%-100%,特异度36%-100%。
核心结论
- 估计子痫前期筛查获益与危害及不同筛查方法测试性能的证据有限。
- 外部验证的风险预测模型适用性有限,缺乏校准和临床实施数据以支持常规使用。
- 需要进一步研究以更好地指导基于风险的筛查方法并改进筛查策略。
研究设计与样本
- 系统综述为美国预防服务工作组提供证据,检索MEDLINE、PubMed和Cochrane中央对照试验注册库从1990年至2015年9月1日,并对目标出版物进行新证据监测至2016年10月5日。
- 纳入英语试验和观察性研究,包括外部验证的预测模型,评估孕期常规子痫前期筛查的有效性、获益和危害。
- 独立双人审查文章摘要和全文,依据预先设定的纳入标准;因纳入研究存在临床和统计学异质性,未进行Meta分析。
- 共纳入21项研究,13982名参与者。
主要发现
- 无研究直接比较筛查人群与未筛查人群的子痫前期筛查有效性;1项美国试验(n=2764)发现减少产前检查次数在获益或危害方面无差异,但针对罕见严重结局的检验效能不足。
- 一项前后对照非劣效性队列研究(n=1952)比较特定指征尿蛋白筛查与常规筛查,未发现减少尿液筛查测试的危害。
- 4项研究(n=7123)报告了16个风险预测模型的外部验证性能,其中5个模型对子痫前期预测具有良好或更好的区分度(c统计量>0.80),在最大、最适用的验证队列中阳性预测值为4%。
- 未报告校准度,尽管校准度是关键模型性能指标。
- 无研究在无症状初级保健人群中评估尿液筛查测试性能;14项研究(n=1888)在疑似子痫前期孕妇中评估尿蛋白检测性能,测试准确性范围宽泛(灵敏度22%-100%;特异度36%-100%),且所用测试、入选标准和蛋白尿患病率(8.7%-93.8%)存在高度统计学和临床异质性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入研究存在临床和统计学异质性,未进行Meta分析。
- 无研究直接比较筛查人群与未筛查人群的子痫前期筛查有效性。
- 1项美国试验(n=2764)针对罕见严重结局的检验效能不足。
- 风险预测模型未报告校准度,且缺乏临床实施数据以支持常规使用。
- 无研究在无症状初级保健人群中评估尿液筛查测试性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Preeclampsia is a complex disease of pregnancy with sometimes serious effects on maternal and infant morbidity and mortality. It is defined by hypertension after 20 weeks' gestation and proteinuria or other evidence of multisystem involvement. OBJECTIVE: To systematically review the benefits and harms of preeclampsia screening and risk assessment for the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed, and Cochrane Central Register of Controlled Trials databases from 1990 through September 1, 2015. Surveillance for new evidence in targeted publications was conducted through October 5, 2016. STUDY SELECTION: English-language trials and observational studies, including externally validated prediction models, of screening effectiveness, benefits, and harms from routine preeclampsia screening during pregnancy. DATA EXTRACTION AND SYNTHESIS: Independent dual review of article abstracts and full texts against a priori inclusion criteria. Meta-analysis was not performed because of clinical and statistical heterogeneity of included studies. MAIN OUTCOMES AND MEASURES: Maternal and infant health outcomes, including eclampsia, stroke, stillbirth, preterm birth, and low birth weight; screening and risk prediction test performance; harms of screening and risk assessment. RESULTS: Twenty-one studies (13 982 participants) were included. No studies directly compared the effectiveness of preeclampsia screening in a screened population vs an unscreened population; 1 US trial (n = 2764) found no difference in benefits or harms with fewer prenatal visits but was underpowered for rare, serious outcomes. For harms, a before-after comparison cohort noninferiority study of urine protein screening for specific indications compared with routine screening (n = 1952) did not identify harms with fewer urine screening tests. Four studies (n = 7123) reported external validation performance of 16 risk prediction models, 5 of which had good or better discrimination (c statistic >0.80) for prediction of preeclampsia, and positive predictive values of 4% in the largest, most applicable validation cohorts. Calibration was not reported despite being a key model performance measure. There were no studies of urine screening test performance conducted in asymptomatic primary care populations; 14 studies of protein urine test performance among women being evaluated for suspected preeclampsia (n = 1888) had wide-ranging test accuracy (sensitivity, 22%-100%; specificity, 36%-100%) and high statistical and clinical heterogeneity in tests used, eligibility criteria, and proteinuria prevalence (8.7%-93.8%). CONCLUSIONS AND RELEVANCE: Evidence to estimate benefits and harms of preeclampsia screening and the test performance of different screening approaches over the course of pregnancy was limited. Externally validated risk prediction models had limited applicability and lacked calibration and clinical implementation data needed to support routine use. Further research is needed to better inform risk-based screening approaches and improve screening strategies, given the complex pathophysiology and clinical unpredictability of preeclampsia.
引用
- Henderson JT, Thompson JH, Burda BU, et al. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017. PMID: 28444285. doi:10.1001/jama.2016.18315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。